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Abstract 
Macrophages are one of the key immune cells within the tumor microenvironment that 
encourage the growth of tumors at the primary site as well as contributing to all parts 
of the metastatic cascade. Although it is possible to isolate macrophages directly, this 
can be a laborious process and due to their plasticity, it is not possible to maintain their 
in vivo phenotype while in vitro.  For this reason, differentiating macrophages from 
bone marrow is an attractive alternative. Here we present robust methods to study in 
vitro derived macrophages including (i) the isolation and generation of macrophages 
from bone marrow,  (ii) differentiation/characterization of classically activated (anti-
tumoral), alternatively activated (pro-tumoral) and tumor-conditioned macrophages, 
as well as (iii) in vitro co-culturing assays for tumor cell-macrophage 
interaction/transmigration. 
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1. Introduction 
Macrophages in vivo can be derived from bone marrow (BM) derived monocytes, fetal 
liver and from yolk-sac-progenitors.  They are usually defined as mononuclear 
phagocytic cells that reside in all tissues and are involved in a wide range of processes 
such as in immune responses and in the regulation of tissue growth and homeostasis 
(Geissmann et al., 2010; Pollard, 2009). In addition, they are involved in almost all 
pathologies either in their resolution or in their acerbation (Wynn, Chawla, & Pollard, 
2013).  In the context of this series, macrophages have been shown in most cases to 
exert pro-tumoral effects within the tumor microenvironment (De Palma & Lewis, 2013; 
Cassetta & Pollard, 2018; Mantovani, Marchesi, Malesci, Laghi, & Allavena, 2017).   
Macrophages in the tumor microenvironment show a different phenotype to 
inflammatory and homeostatic cells (Qian & Pollard, 2010) and exert functions that 
enhance cancer malignancy at every step of the metastatic cascade. These functions 
include the induction of angiogenesis, enhancement of tumor cell dissemination to 
metastatic sites where they also enhance extravasation and metastatic cell survival 
and growth (Kitamura, Qian, & Pollard, 2015). They also produce an 
immunosuppressive microenvironment which contributes to 
immunotherapy/chemotherapy resistance (Cassetta & Pollard, 2018; DeNardo & 
Coussens, 2007). The link between poor prognosis and high macrophage infiltration 
has also been established in many but not all human cancers (Jochems & Schlom, 
2011; Yang, McKay, Pollard, & Lewis, 2018). Besides pro-tumoral macrophages, the 
release of inflammatory factors in the tumor microenvironment such as IFN-γ, could 
activate tumoricidal macrophages that enhance an anti-tumor immune response 
however the persistence of this phenotype within an immunosuppressive tumor 
microenvironment is unclear (Mantovani & Sica, 2010). Recent studies have shown 
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that macrophages can be therapeutically be reprogrammed using agonistic or 
antagonistic drugs and thereby be diverted to fight against cancer. (Cassetta & Pollard 
2018).  
In mice, bone marrow derived CD11b+CD11c-Ly6G-Ly6Chigh/low circulatory monocytes 
are recruited to the tissue and differentiate into Ly6C-F4/80+CD11b+ macrophages. 
These cells populate inflammatory tissue and are present in large numbers in the 
tumor microenvironment (Epelman, Lavine, & Randolph, 2014) as well as many 
tissues during homeostasis such as the intestine, replacing yolk sac derived 
macrophages. Macrophages are highly versatile cells that display a wide spectrum of 
phenotypes. Despite this fact they are often over-simplistically classified as classically 
activated macrophages that play an immune effector/anti-tumoral role, and 
alternatively activated macrophages that play an immunoregulatory/pro-tumoral role 
(Gordon & Taylor, 2005; Mosser & Edwards, 2008) This nomenclature has also been 
superimposed upon the classification of “M1 or M2’ based observations in different 
mouse strains with different susceptibilities to cancer (Mantovani & Sica, 2010) to 
reflect Th1 and Th2 responses in vivo. However, this classification is more 
representative of in vitro derived macrophages using cytokine-mediated differentiation 
rather than their phenotype of in vivo. To clarify these responses, Murray and 
colleagues suggest a nomenclature that links to the cytokines used for the activation 
such as M(IL-4), M(IL-10) (Murray et al., 2014) at least in vitro.  But the situation in 
vivo is likely to represent a much more mixed phenotype given the plethora of signals 
such cells respond to (Cassetta et al., 2019).  
Although it is possible to sort macrophages from digested tissues, samples can be 
scarce, and this can be a time consuming and expensive process with high variability 
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between subjects/animals. Consequently, the development of means to isolate 
macrophages from bone marrow originally perfected by Stanley (Stanley, 1985, 1997; 
Tushinski et al., 1982) has provided a boon to studies of macrophage biology.  This is 
because large numbers of cells at greater than 95% purity can be obtained from a 
small number of mice (approximately 10-15 million bone marrow cells can be isolated 
from a mouse femur) and the isolation protocol and differentiation is straight-forward 
and cost-effective. These cells respond by proliferation to the growth factors Colony 
stimulating factor (CSF)1, CSF2 and IL-3 and they can be polarized in vitro with a wide 
range of factors. At least 95-98% of these cells are dependent on CSF1 for viability 
(Stanley, 1985; Tushinski et al., 1982). Furthermore, the ability to isolate them from 
any mutant mouse that contains a null or conditional allele of any gene of interest 
allows studies on growth factor signalling and macrophage function. In addition, there 
are studies where these bone-marrow derived macrophages (BMDMs) or their 
conditioned medium (CM) can be transferred to recipient mice and functions studied 
in vivo (Saha et al., 2016; Thomas et al., 2011).   
Although BMDM isolation is a widely used protocol for in vitro macrophage studies 
there is a diversity of methods for their maturation and differentiation. Therefore, in 
this chapter we aim to demonstrate a standard BMDM isolation, methods for 
differentiation with cytokines/growth factors and for studying the roles of macrophages 
in tumor biology.  
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2. Isolation and Differentiation of Murine BMDM 
2.1 Introduction 
BMDM isolation shows methodological differences among various studies but as yet 
it is unclear whether those differences affect functional outcome. Some important 
steps in this protocol should be noted to reduce the variation among different isolation 
methods.  For example, to increase the purity of hematopoietic stem cell isolation, we 
used tissue culture plates on the first day of isolation to allow mesenchymal stem cells, 
fibroblasts, mature macrophages and other adherent cells to attach but allow 
hematopoietic cells to be free within the medium. We then transfer the cell suspension 
into a low adhesive petri plate to continue their differentiation. In addition, different 
BMDM seeding densities are used among various methods and it has been shown 
that higher seeding densities might affect macrophage phenotype (Lee & Hu, 2013). 
In this protocol, seeding 3x106 cell per 10cm2 dish gave a pure Ly6C-Ly6G- 
CD11b+F4/80+ macrophage population as shown in Figure 1. Both human and mouse 
recombinant CSF1 (historically often called macrophage-CSF, M-CSF) can be used 
for differentiation. Human recombinant CSF1 has been shown to be fully effective for 
mouse BMDM differentiation (Stanley, 1985, 1997). We analysed BMDM phenotype 
on day 8, although BMDMs can be used for up to 3 weeks after differentiation as 
previously reported (Davies & Gordon, 2005). They can also be frozen down for use 
later. 
2.2 Collection of Mouse Femur and Tibia 
1. Euthanize the mouse according the approved animal license procedure.  
2. Place the mouse in supine position and disinfect the legs and the hips by 
spraying with 70% (v/v) Ethanol.  
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3. Using scissors cut the skin along the inguinal area and pull back the entire leg 
skin.  
4. Remove the quadriceps and the tibias anterior muscle with forceps or a blade, 
until femur and tibia bone is visible.  
5. Using forceps twist the femur and dislocate the femoral head from the hip with 
scissors. Make sure the femur is not damaged.  
Note: Bones could be stored or shipped in 45 ml of fetal bovine serum free 
DMEM medium supplemented with 1% (v/v) Penicilin Streptomycin at 4°C for 
1-3 days. The effect of storage on BMDM isolation is characterized by Papazian 
et al. (Papazian, Kfoury, Scadden, 2017)  
6. After the femur is completely dislocated from the cadaver, using forceps twist 
the knee joint between femur and tibia. Cut the knee joint and connective tissue. 
Make sure the tibia is not damaged. 
7. Repeat the same procedure to dislocate distal tibia from talus.  
8. Remove the excess muscle and connective tissue using sterile 70% ethanol-
soaked tissue wipes and a blade.  
9. Place the femurs and tibias on a petri dish and place them on ice.  
 
2.3 Bone Marrow Isolation 
 
1. Under the sterile laminar flow hood, hold the femur or tibia using forceps and 
gently cut the tip of the proximal and distal epiphysis of the bone. Make sure 
metaphysis of two edges are exposed.  
2. Hold the bone in a vertical position and gently insert a 271/2G needle from the 
proximal metaphysis. Using a 5ml syringe, flush 5ml of cold phosphate buffered 
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saline (PBS), (without calcium chloride or magnesium chloride, pH 7.4) into a 
50ml empty falcon tube.   
3. Rotate the bone upside down and repeat the same procedure from the distal 
metaphysis side.  
4. Using a 1 ml pipette, mix the bone marrow cell suspension to homogenize into 
a single cell suspension. 
5. Pass the suspension through a 70μm cell strainer to remove any bone 
fragments and blood clots. 
6. By using the cap of a 1ml plunger, homogenize any bone marrow fragments 
that remain on 70μm cell strainer. Wash the filter with 5ml more PBS.  
7. Centrifuge at 400 g for 5 min at 4°C.  
8. Discard the supernatant and re-suspend the pellet in 30mL of PBS.  
9. Take 20μl of homogenized cell suspension and count the cell number using 
manual or automated cell counter.  
10. Centrifuge at 400g for 5 min at 4°C.  
11. Discard the supernatant. 
 
2.4 BMDM maturation and differentiation 
 
1. Re-suspend the cells with alpha-MEM medium (Gibco, Cat #: 12571063) 
supplemented with 10% v/v fetal bovine serum (FBS), (Gibco, Cat #: 11573397) 
and 1% v/v penicillin streptomycin (PS) (Gibco, Cat #: 15140122) at a 
concentration of 3x105 cell/ml. 
2. Split 10 ml of cell suspension to each tissue culture treated 10cm2 plate.  
3. Add 4.4nM (104U/ml) recombinant CSF1 to each plate.  
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4. Incubate cells in a humidified incubator with 5% CO2 at 37°C  
5. 24h later, transfer non-adherent cells into a non-tissue culture treated petri dish. 
Note: This procedure is required to remove adherent mesenchymal stem cells.  
6. Replace the medium and 4.4nM (104U/ml) of recombinant CSF1 every 2-3 
days.  
Note: CSF1 consumption rate/cell density is described in detail by Tushinski et 
al. (Tushinski et al., 1982) 
7. For the first 3 days cells will not be adherent, therefore add fresh CSF1 and top 
up to 10ml final volume.  
Note: Bone marrow cells that are in 3-4 days in culture could be stored in 10% 
v/v DMSO FBS solution in -196°C for the long term. 
8. For subsequent days aspirate the media and add fresh CSF1 and medium to 
adherent cells on the plate. 
9. On Day 7 collect the cells for analysis or for differentiation. 
10. To collect cells, place the cell culture plate on ice, aspirate the medium and 
wash the plates with ice cold PBS. Add 5mL alpha-MEM medium and using a 
cell scraper gently scrape the bottom of the plate and collect the macrophages.  
11. Collect the cell suspension into a 50mL falcon tube, centrifuge at 400g for 5 min 
at 4°C.  
12. Process cells for analysis or seed 2x105 cells per 6-well plate with 3ml alpha-
MEM full medium with 4.4nM CSF1 for differentiation.  
13. To differentiate them into different macrophage subtypes, M(IFNγ+LPS), 
M(IL4+IL13) and tumor conditioned macrophages (TCM) use the reagent mix 
shown in Table 1 and Table 2. 
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Note: Tumor-conditioned medium (CM) can be collected from any murine or 
human tumor cell line, not forgetting species difference in response to factors. 
In this assay we used the murine mammary carcinoma E0771 cell line. Briefly, 
seed 1x106 tumor cells into 75cm2 flask using DMEM medium supplemented 
with 10% v/v FBS. 24h later when cells are 70-80% confluent, collect the 
medium and centrifuge at 400g for 5 minutes. Filter the medium using 0.44μm 
low protein binding syringe filter. Transfer the supernatant into a new Falcon 
tube. Use the CM fresh or freeze in aliquots at -80°C. Use 20% v/v of this 
medium for BMDMs differentiation.  
14. 24h after differentiation aspirate the medium and wash the plates with PBS. 
15. Aspirate PBS and add 1ml of Accutaseâ (Sigma-Aldrich, Cat # A6964) to each 
well.  
Note: Because differentiated cells are more adherent, accutase will help cells 
to detach from the plate.  
16. Incubate cells for 15-20 min at 37°C.  
17. Place the cell culture plate on ice and using a cell scraper gently scrape the 
bottom of the plate and collect macrophages.   
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3. Characterization of mouse BMDM phenotype 
3.1 Introduction 
While BMDMs are an incredibly useful model to study macrophage function in vitro, 
for some of the reasons mentioned above, it’s important to establish standard 
characterization methods to reduce the variability between different in vitro 
experiments and to validate their phenotypic similarities to in vivo macrophage 
subtypes.   
There are a variety of ways to do this one of which is flow cytometry. Flow cytometry 
is a convenient and effective method allowing a researcher to accurately and 
simultaneously analyze several cell surface and intracellular markers by 
immunolabeling cells, allowing the identification of sub-populations that may exist 
within the BMDM preparation (e.g. mesenchymal stem cells, dendritic cells etc.), while 
gating out any other cell population of interest that could be co-cultured with BMDM.  
It is important to select markers that successfully distinguish different macrophage 
subtypes clearly. There are a number of cell surface markers that could be used for 
phenotypic characterization using flow cytometry. With no exception they will all show 
CSF1R+ (CD115) and F4/80 positivity (Table 3). To identify different subtypes here we 
have selected CD86, CD206 and MHC-II markers. CD86 is a co-stimulatory molecule 
that is the most upregulated in classically activated macrophages (Gensel, Kopper, 
Zhang, Orr, & Bailey, 2017) or M(IFNγ+LPS) and successfully distinguishes it from 
both alternatively activated macrophages or M(IL4+IL13) and those treated with TCM 
(Figure 1C). CD206 is a mannose receptor that is upregulated on M(IL4+IL13) (Stein 
et al., 1992) and TCM (Figure 1C). As well as these markers, MHC-II can be used in 
combination with the above to distinguish TCM from the other macrophage subtypes. 
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For example, M(IFNγ+LPS) are CD86hi, CD206lo, MHC-IIhi while M(IL4+IL13) are 
CD86lo, CD206hi and MHC-IIlo and TCMs are CD86lo, CD206hi and MHC-IIhi. 
 
3.2 Staining and controls  
1. Collect cells from petri plate as described in 2.4. Centrifuge them at 400g for 5 
mins at 4°C.   
2. Discard supernatant and homogenize pellet with 5mL of flow cytometry buffer 
(5% w/v bovine serum albumin in 1x PBS, pH 7.4). 
3. Centrifuge at 400g for 5 mins at 4°C. 
4. Discard supernatant and resuspend with flow cytometry buffer on ice. 
5. Pass suspension through 70μm cell strainer to ensure a single cell suspension. 
6. Count cells and aliquot 0.5-1x106cells/100μL to flow cytometry tubes on ice- 
label appropriately (Samples and controls listed in Table 4) 
7. Add 1μl of Fc blockTM (CD16/CD32) (BD Pharmingen, Cat #: 564219) per 
1x106cells on ice for 10 mins. 
8. Add antibody cocktail (Table 4-5) and incubate on ice for 30-60mins.  
9. Add 1-2mL flow cytometry buffer to each tube and centrifuge at 400g for 5 mins 
at 4°C. Discard the supernatant and repeat the wash step one more time.  
10. Resuspend in 300μL flow cytometry buffer and add 0.3μl of 100μg/ml DAPI 
before running the samples on flow cytometer. Make sure samples are 
thoroughly mixed.  
 
3.3 Data acquisition and gating strategy (DIVA software, BD 6laser-LSR) 
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1. Acquire unstained cells to set up the correct voltages for forward scatter (FSC) 
and side scatter (SSC). Make sure all cells are on scale and the main cell 
population is distinct from cell debris.  
2. Prior to fluorescence compensation setup, run an unstained and a fully stained 
sample to make sure that none of the colors are off-scale. The unstained 
histogram should be around 102 in logarithmic scale and fully stained should be 
under 105. 
3. Run compensation beads (eBioscience) stained with a single antibody. This will 
result in a proportion of stained and unstained beads. Follow the software’s 
usual method for compensation. 
4. Start acquiring your samples. When acquiring data, set the ‘stopping gate’ to 
the CD11b+, F4/80+ gate (See Figure 1A) and collect at least 10,000 events 
within this gate. These are considered the macrophages. These gates can be 
set up by gating on positive cells compared to their respective FMO. 
5. Save all of your data onto appropriate software/hardware for further analysis on 
your preferred analysis software.  
 
4. BMDM Cancer Cell Co-culture Assays 
4.1 Introduction  
Macrophages induce tumor cell progression, survival and migration through reciprocal 
cell-cell interactions in vivo. Several of these activities can be mimicked in cell culture 
thus allowing exploration of mechanism that in turn can be re-explored within in vivo 
models.  We have performed a number of these assays over the years describing for 
example, a paracrine loop between TAMs and tumor cells involving tumor synthesized 
CSF1 and macrophage produced EGF ligands (Condeelis & Pollard, 2006). Most 
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recently we have studied the mechanism whereby macrophages promote metastasis 
via their stimulation of extravasation and tumor cell survival at metastatic sites 
(Kitamura & Pollard, 2015). To this end we developed relatively simple assays 
involving two-or three-cell types that have high fidelity when translated back in vivo.  
These assays allow screening using mutant BMDM and inhibitors to establish function. 
One such assay we use is the “In vitro transendothelial migration” (eTEM) assay which 
is designed to mimic the extravasation of tumor cells and thus combines tumor and 
endothelial cells with macrophages.  A similar assay was also developed for 
intravasation (Wyckoff et al., 2004). For the eTEM assay macrophages are seeded on 
the underside of a transwell, while the upper-side is coated with matrix and endothelial 
cells. Cancer cell extravasation from the apical side of endothelial cells to the 
macrophage rich underside is quantified. This assay has previously been used to 
demonstrate that inflammatory monocytes as well as VEGF and CCL3 expression in 
metastasis-associated macrophages promotes cancer cell transmigration (Kitamura 
et al., 2015; Qian et al., 2011). Time-lapse imaging is a second method used in the 
same study to demonstrate tumor cell-macrophage cell-cell interactions and thus 
showed that CCR1 expression is required by macrophages to interact with cancer 
cells (Kitamura et al., 2015).  Below is a detailed description of these two assays.  It 
should be acknowledged that there are many other types of assays published that look 
at tumor cell-macrophage interactions often using sophisticated microfluidic devices 
see for example (Zervantonakis et al., 2012) or spheroid type assays. Readers are 
referred to this large literature to select the assay most suitable to their needs.   
 
4.2 In vitro Transendothelial Migration Assay 
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1. 2 days before the experiment: For migration assays use a growth factor 
reduced matrigel coated 8μm pore size transwell insert (Corning, Cat #  
354483). Thaw the inserts at room temperature for about 10min. 
2. Preincubate the transwells with DMEM (Corning, Cat # 10-013CVR) medium 
and 10% v/v FBS by adding 300μl on upper chamber and 500μl on bottom 
chamber. Incubate at 37°C for 2 hours.  
3. Preparation of 3B-11 cells (SV40 transformed mouse endothelial cell line):  
a. Culture 3B-11 cells in DMEM medium supplemented with 10% v/v FBS.  
b. Aspirate the medium and wash cells with 1x PBS. Aspirate the buffer 
c. Add 3ml Trypsin-EDTA (0.25%) (Gibco) on T75cm2 flask 
d. Incubate 5min at 37°C. Stop the enzymatic process by adding 3ml of 
DMEM complete medium. Collect detached cells into a 15ml falcon tube  
e. Centrifuge cells at 400g for 5min. Discard the supernatant.  
f. Resuspend cells in DMEM complete medium. Adjust the cell 
concentration to 105 cells per/ml. 
4. Aspirate the medium on both sides of the transwells. Make sure matrigel and 
membrane is not damaged.  
5. Add 200μl of the 3B-11 cells suspension on top of the matrigel and add 750μl 
DMEM medium on the bottom chamber. Incubate cells for 48h at 37°C in 5% 
CO2 until cells form a monolayer over matrigel.  
Note: Incubation times can vary according to standardization methods 
described at 4.3. 
6. On the experiment day: Prepare and label E0771 cells (mouse breast 
adenocarcinoma cell line, cells are cultured in same condition as 3B-11 cells):   
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a.  Aspirate the cell culture medium from T75cm2 flask and wash cells with 
prewarmed PBS.  
b. Add 10ml of pre-warmed serum free DMEM and 1μM Cell Tracker Green 
CMFDA Dye (Thermo Fisher). Incubate cells for 15min at 37°C in 5% 
CO2 
c. First check the staining under the microscope.  
d. Aspirate the medium and repeat step 4.2.3(a-e) to collect cells.  
e. Centrifuge cells at 400g for 5 min. Discard the supernatant and wash 
cells with 1X PBS.  
f. Repeat the centrifuge step. Discard the supernatant. Resuspend the 
cells in DMEM medium with 0.5% v/v FBS and 4.4nM CSF1. Adjust the 
cell concentration to 2x105 cells. Keep the cells on ice until migration 
assay is ready to start.  
7. Preparation of macrophages  
a. Use BMDMs 7 days after maturation and collect macrophages from 
tissue culture plates as indicated in section 2.4  
b. Centrifuge macrophages at 400g for 5min, discard the supernatant  
c. Resuspend cells in DMEM complete medium with 4.4nM CSF1 and 
adjust the concentration to 5x105 cells/ml 
d. Aspirate the medium from transwells and make sure endothelial cells, 
matrigel and transwells are not damaged. Using a sterile tweezer flip the 
membrane upside down on 24-well plate-lid.  
e. Seed 20μl of macrophage suspension on the underside of the transwell 
and let the macrophages attach for 15min under the hood at room 
temperature.  
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Note: Make sure there are no bubbles and the solution are dispersed evenly 
on the membrane 
f. Place the inserts back into the empty 24 wells and let the cells attach for 
another 15min in the hood.  
Note 1: Since endothelial cells will be attached on the matrigel, they won’t 
get dry during the 30min incubation.  
Note 2: Step 6 and step 7 could be initiated at the same time and preparation 
could be coordinated between the waiting time of each step. However as 
soon as macrophages are attached to the transwell transmigration assay 
needs to be started. Tumor cells should be kept on ice until they are ready 
to be placed on transwells for the transmigration. 
8. Move transwells to a 12 well plate with 750 μl of 4.4nM CSF1 and DMEM 
complete medium.  
9. Add 200 μl of tumor cells suspension on top of the transwell.  
10. 36 hours later, aspirate the medium from top and bottom chamber and fix 
transwells with 4% w/v paraformaldehyde (PFA) solution for 15min at room 
temperature.  
11. Remove PFA and wash transwells twice with 1X PBS. To remove non-migrated 
cells, scrub the upper side of the transwells with a cotton swab.  
12. Transfer the wells into a 35mm Mat-Tex glass bottom dish. Using an inverted 
light microscope equipped with 20X (NA+0.40 air) objective and cooled CCD 
camera, take 20X images from 6 fields. Quantify the number of migrated cells 
using Fiji/Image J software. The images from multiple fields can be analyzed in 
batches. Convert images into a grayscale, and by using the threshold tool, 
create binary images (positive pixels in black, background white). By using 
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analyze particle feature, select the average size of a cells and count the number 
of the cells on the membrane. (If the number of migrated cells per 20X is low, 
cells could be also counted manually).   
13. To obtain more accurate results, the whole transmembrane can be imaged 
using a whole slide scanner microscope. To block the autofluorescence caused 
by the transmembrane, use a Matrigel coated membrane that blocks 
transmission of light between 400 and 700nm (FluoroblokTM, Corning, 354165) 
a. Repeat the same procedure until step 12.  
b. Cut the membranes from the transwell by using a scalpel. Using fine 
tweezers transfer the membranes onto a glass slide. 
c. Place each membrane on a glass slide with the underside of the 
transwell membrane facing up. Wash membranes with 1X PBS.  
d. Aspirate PBS buffer and counterstain by adding 100μl of 0.5μg/ml DAPI 
in PBS. Incubate at room temperature for 10 minutes.  
e. Aspirate the DAPI solution, wash membranes twice with PBS.  
f. Aspirate PBS and mount membranes using mounting medium (Prolong 
Diamond, Thermo Fisher) and seal with coverslip. 
g. After 24 hours when mounting medium is polymerized and coverslip is 
stabilized, image the entire membrane using a fluorescent whole slide 
scanner with 20x magnification. Acquire whole slide fluorescence 
images within 358nm excitation and 461nm emission for DAPI and 
492nm excitation and 517 emission for cell tracker green. (AxioScan Z1 
Slide scanner, 20X magnification) 
14. Process auto-stitched tile images using an image processor (i.e. Definiens AG, 
Tissue Studio). Detect cell tracker positive tumor cells by using a nuclear 
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detection and cell simulation algorithm. Detect DAPI and Cell Tracker positive 
cells on the entire membrane and run the batch analysis for all samples.  
Note: This algorithm can be already built-in to the image processor 
software such as in Definiens AG, Tissue Studio, or new algorithms 
could be created using average nucleus/cell size and staining 
thresholding parameters.  
4.3 Standardization methods to obtain endothelial cell monolayer for eTEM 
assay  
The methods described below are used to determine an optimum incubation time for 
endothelial cells to form a confluent monolayer.  
 
1. Repeat step 4.2 (1-4). Incubate endothelial cells for 24, 48, 72 or 96 hours at 
37°C in 5% CO2. A transwell insert with no cells must also be included. 
2. Trans-endothelial resistance: 
a.  Replace DMEM complete medium with DMEM 0.5% v/v FBS, 1mM 
sodium pyruvate, 1% v/v PS.  
b. Two hours later measure the transendothelial resistance using EndOhm-
6 chamber and EVOM2 resistance meter (World Precision Instruments) 
or equivalent. 
c. Express resistance values (W) recorded in function of the effective 
surface area of the filter membrane (Wxcm2)  
3. Endothelial permeability:  
a. Repeat step 4.2 (1-4)  
b. Replace the upper and bottom chamber medium with phenol red free-
DMEM, 0.5 % v/v FBS, 1mM sodium pyruvate, 1% v/v PS and 100μl/ml 
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70kDa Rhodamine B Isothiocyanate-Dextran (TRITC), (Sigma-Aldrich) 
and incubate the cells for 36 hours.  
c. Take 100μl of samples from the top and bottom chamber. Dilute samples 
collected from the top chamber 1:5 in phenol-red free DMEM.  
d. Read the fluorescence at emission at 586nm (excitation T 557nm) using 
a microplate reader.  
e. Calculate the TRITC concentration based on a standard curve for 
TRITC.  
f. Determine the optimum incubation time for endothelial cells when no 
TRITC is detected on the bottom chamber and TER has the highest 
value compared to the other incubation time.  
4.4 2D Coculture Time-Lapse Imaging  
1. Preparation of Matrigel coated chamber slides.  
a. Add 300μl of 5mg/ml Matrigel (Corning) in alpha-MEM into each well 
of Lab Tek II 4-well Chamber Slide (Nunc).  
b. Incubate the slides for 1hr at 37°C.  
2. During the incubation time of Step 1b, start preparation and labeling of 
macrophages: 
a. Prepare bone marrow-derived macrophages as shown in procedure 
2.4 (step 3-6).  
b. Replace the medium to pre-warmed serum free alpha-MEM medium 
with 1.25μm Cell Tracker Orange CMTMR Dye (Thermo Fisher).  
c. Incubate cells for 15min at 37°C in 5% v/v CO2  
Note: During this incubation time, tumor cells could be prepared (step 
3.  
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d. Isolate the labelled macrophages as described in procedure 2.4 
(Step 10)  
e. Centrifuge cells at 400g for 5 min. Discard the supernatant and wash 
cells with 1x PBS.  
f. Repeat the centrifuge step. Discard the supernatant. Resuspend the 
cells in alpha-MEM complete medium with 4.4nM CSF1.   
3. Preparation of E0771 cells.  
a. After repeating procedure 4.2.5.2a-e, discard the supernatant and 
resuspend the cells in alpha-MEM complete medium.  
4. Aspirate the medium and add 104 E0071 cell and 104 BMDMs in total 1mL 
of alpha-MEM complete medium with 4.4nm CSF1, and gently add to 
Matrigel coated chamber slides. Let them attach to the plate for 1hr at 37°C 
in 5% CO2 
5. Use an inverted microscope with 10x magnification, motorized stage, CCD 
camera sensitive for time-lapse imaging (Axiovert 200, Zeiss) and equipped 
for microscope cage incubator. Set the incubator for 5% v/v CO2 and 37°C.   
Acquire brightfield and fluorescent images every 10 minutes on 10 randomly 
selected fields.  
Note: In the current staining protocol the staining intensity and exposure 
time is kept minimal to reduce phototoxicity. Any modification of the 
current protocol requires optimization to keep the cell status healthy.   
6. Process movies in Fiji/ImageJ software and track macrophage-tumor 
interaction using a manual-tracking tool in the software. Transfer the data to 
a spreadsheet and calculate the mean of interaction (in minutes) and the 
percentage of interacting cells.  
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Note: The examples of the movies and quantification results are in 
Kitamura et al., 2015)  
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Concluding Remarks 
 
In this study we have shown a reproducible macrophage differentiation and 
characterization method using murine bone marrow derived macrophages and 
introduced two coculture methods to study macrophage-tumor interactions.  Cytokine 
doses used for macrophage differentiation have been tested and characterized in 
many other studies (Cho et al., 2014; Zajac et al., 2013; Zhao et al., 2017), however 
the dose of conditioned medium used for tumor-conditioned macrophages needs to 
be optimized for each experiment. The confluency of tumor cells, the origin of cell 
lines, the type of the medium, the batch of FBS and storage conditions might affect 
the quality of the conditioned medium and macrophage differentiation. To improve the 
reproducibility, these parameters need to be kept the same between each experiment.  
 
We demonstrated three of the most commonly studied macrophage subtypes in vitro. 
Although macrophages are differentiated through LPS stimulation do not represent a 
tumor-associated macrophage phenotype but instead a bacteriocidal phenotype, 
reprogramming alternatively activated macrophages into classically activated 
macrophages has been shown to promote an anti-tumoral effect and macrophage 
reprogramming has been studied in vitro (Genard, Lucas, & Michiels, 2017). Using 
LPS or IFNγ stimulation decreases CSF1 receptor level of BMDMs in vitro therefore 
macrophage polarization should be induced after BMDMs are grown in CSF1 rich 
medium (Stanley, 1985). In addition, BMDMs derived from C3H/HeJ and C57BL/10Scr 
strains are not responsive to LPS stimulation and this allows for testing of reagents 
that may be contaminated by endotoxin (Guilbert & Stanley, 1984; Poltorak et al., 
1998).  It is also possible to use TNF-α rather than IFN-γ for activated macrophage 
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differentiation (Martinez, Sica, Mantovani, & Locati, 2008). Thus, it is absolutely 
necessary to define treatments rather than give generic descriptions to macrophage 
types.  
 
Cytokine mediated differentiation causes changes in expression of a wide variety of 
cell-surface and intracellular markers, and flow cytometry is a robust method to 
characterize and monitor those changes. In our study we selected a set of markers 
that shows the evident differences between M(IFNγ+LPS), M(IL4+IL13) and TCM, 
however marker choice can be enriched by using other markers (Table 3). 
We describe two tumor-macrophage coculture assays that have been validated in our 
earlier studies. Transmigration models of extravasation could be adapted for tumor 
intravasation (iTEM) by changing the order of cells seeded in the transwells such that 
the macrophages and tumor cells are co-cultured together on top of the filter with 
CSF1 in the lower chamber (Pignatelli et al., 2014). 2D macrophage-tumor coculture 
assays are a robust method to study the direct interaction of those cells, yet to mimic 
the complexity of tumor microenvironment more advanced 3D models can be also 
used (Rebelo et al., 2018). 
 
It is important to note that in vitro macrophage differentiation is in fact an 
oversimplification of the actual in vivo situation. Macrophages are highly susceptible 
to changes within the extracellular environment and they display a wide spectrum of 
subtypes (Mosser & Edwards, 2008) particularly in the tumor microenvironment 
(Condeelis & Pollard, 2006). Indeed, the exact mechanisms of in vivo differentiation 
and macrophage ontogeny in some tissues are still not well known and this makes it 
difficult to define a standard method for macrophage characterization in vivo. 
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Nevertheless in vitro macrophage differentiation and in vitro co-culture studies 
continues play an essential role to reveal fundamental mechanisms.  
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Tables  
 
 
Table 1. BMDM Differentiation Reagents 
Macrophage subtype Reagents 
M(IFNγ+LPS) or ‘Activated’  IFN-γ + LPS 
M(IL4+IL13) or ‘Alternatively activated’  IL-4 + IL-13 
Tumor conditioned macrophages 
(TCM) 
20%v/v Tumor-conditioned medium 
 
 
Table 2. Differentiation Reagents  
Differentiation 
Reagents 
Final 
Concentration 
Catalogue 
Number 
Supplier 
IFN-γ  20ng/ml  315-05 Peprotech 
LPS 100ng/ml  297-473-0 Sigma-Aldrich 
IL-13  20ng/ml 210-13 Peprotech 
IL-4  20ng/ml  214-14 Peprotech 
 
Table 3. Suggested cell surface markers for identification of BMDM subtype via flow 
cytometry 
BMDM subtype Markers 
Pan-macrophage (lineage) CD45+, Ly6C-, Ly6G-, F4/80+, CD115+ 
CD11b+ 
M(IFNγ+LPS) or ‘Activated’ CD80+, CD86+, MHC-IIhigh, TLR-4+ 
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Table 4. Samples staining and controls for flow cytometry 
Tube name Samples to 
be stained 
Ab’s to be used 
Unstained Cells  No Ab’s- just buffer and Fc Block 
Full stain Cells All Ab’s + DAPI 
Isotype controls Cells All Ab’s, swap one Ab for its 
isotype control instead + DAPI 
Fluorescence-minus one 
controls (FMO) 
Cells All Ab’s apart from Ab of interest+ 
DAPI 
Compensation Controls Beads Single Ab  
 
 
Table 5. Antibody list for immunolabeling  
Antibody Dilution Cat. No. Company 
CD45-PerCPCy5.5 1/100 109827 BioLegendÒ 
Ly6C-BV711 1/100 128037 BioLegendÒ 
Ly6G-BV510 1/200 127633 BioLegendÒ 
CD11b-BV605 1/200 101237 BioLegendÒ 
F4/80-APC 1/50 MCA497-A647 Bio-Rad 
CD86-APCCy7 1/100 105029 BioLegendÒ 
M(IL4+IL13) or ‘Alternatively 
activated’ and TCM  
CD206+, Arg1+, CD163+, CD204+, 
CD209+CD169+ MHCIIhigh/low 
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MHC-II-FITC 1/00 107605 BioLegendÒ 
CD206-PECy7 1/100 141719 BioLegendÒ 
Isotype ctrl for CD86 1/100 400523 BioLegendÒ 
Isotype ctrl for MHC-II  1/100 400633 BioLegendÒ 
Isotype ctrl for CD206  1/100 40052 BioLegendÒ 
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Figure Legends 
Figure 1. A. Flow cytometry gating strategy to identify BMDM B. Geometric mean Bar 
charts and C. Histograms showing the expression of BMDM markers exposed to 
M(IFNγ+LPS), M(IL4+IL13), TCM polarizing conditions. The color legends are same 
in B and C. D. Flow cytometry dot plots of M(IFNγ+LPS), M(IL4+IL13), TCM showing 
the expression of different BMDM markers 
 
 
